RenovoRx RNXT
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
RenovoRx (RNXT) Business Model and Operations Summary
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
Key Insights
RenovoRx (RNXT) Core Market Data and Business Metrics
Latest Closing Price
$0.96Market Cap
$35.56 MillionAverage Daily Trade Volume
139,640 SharesPrice-Earnings Ratio
-1.66Total Outstanding Shares
35.53 Million SharesCEO
Mr. Shaun R. BagaiTotal Employees
8Dividend
No dividendIPO Date
August 26, 2021SIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQHeadquarters
333 W. Santa Clara Street, Suite 900, San Jose, CA, 95110
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Operating Activities | $-8.75 Million |
| Net Cash Flow From Investing Activities | $-8.39 Million |
| Net Cash Flow From Investing Activities, Continuing | $-9.55 Million |
| Net Cash Flow, Continuing | $-3.22 Million |
| Net Cash Flow From Financing Activities | $15.09 Million |
| Net Cash Flow | $-3.22 Million |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Income/Loss Available To Common Stockholders, Basic | $-9.16 Million |
| Diluted Average Shares | $21.46 Million |
| Nonoperating Income/Loss | $952,000 |
| Operating Income/Loss | $-10.12 Million |
| Income/Loss From Continuing Operations Before Tax | $-9.16 Million |
| Net Income/Loss | $-9.16 Million |
Comprehensive Income
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Other Comprehensive Income/Loss | $-17,000 |
| Comprehensive Income/Loss Attributable To Parent | $-9.16 Million |
| Comprehensive Income/Loss | $-9.16 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Liabilities And Equity | $10.03 Million |
| Equity Attributable To Noncontrolling Interest | $0 |
| Assets | $10.03 Million |
| Current Assets | $10.03 Million |
| Noncurrent Assets | $0 |
| Liabilities | $2.96 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||